Andere talen Aurinia Pharmaceuticals Inc.

Aandelen

AUPH

CA05156V1022

Geschatte realtime Cboe BZX Andere beurzen 20:44:48 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,885 ^USD	+1,56%		-3,92%	-45,49%

20/03	ILJIN SNT stuurt een brief naar Aurinia Pharmaceuticals	CI
07/03	Aurinia Pharmaceuticals Insider verkocht aandelen ter waarde van $711.094, volgens een recente SEC filing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

UPDATE, NEW AURINIA PRESENTATION DETAILS AT THE 2024 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE	17/04
New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference	16/04
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024	15/04
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	20/03
Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	07/03
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing	07/03
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program	29/02
Aurinia to Participate in Upcoming Investor Healthcare Conferences	27/02
Sector Update: Health Care Stocks Higher Late Afternoon	15/02
Sector Update: Health Care Stocks Higher Thursday Afternoon	15/02
Sector Update: Health Care	15/02
Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	15/02
Aurinia: Q4 Earnings Snapshot	15/02
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	15/02
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q4 Revenue $45.1M, vs. Street Est of $45.2M	15/02
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value	15/02
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024	15/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Aurinia Pharmaceuticals Inc.

Aandelen

AUPH

CA05156V1022

Andere talen

Filters